<DOC>
	<DOC>NCT01354665</DOC>
	<brief_summary>This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations. The study is conducted in routine practice setting hence no interference with standard care takes place. Pharmacologic treatments of MS-fatigue and depression will also be recorded.</brief_summary>
	<brief_title>Depression and Fatigue in MS Patients Treated With Betaferon.</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Relapsingremitting multiple sclerosis Age 18+ Patients initiating Betaferon treatment Patients previously treated with any immunomodulatory drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Interferon beta-1b</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Depression</keyword>
</DOC>